WHO adds two vaccine candidates to Ebola trial in DR Congo
Expert groups convened by the World Health Organization have suggested including two additional vaccine candidates in the Tumaini clinical trial currently underway in the Democratic Republic of the Congo.
These candidates are ChAdOx1 from the University of Oxford and the Serum Institute of India, alongside Moderna’s mRNA-1469.
According to the organization, this marks the first time vaccines targeting the Bundibugyo virus will be tested during an active outbreak. The trial, led by the Institut National de Recherche Biomédicale, uses a ring-vaccination method to enroll contacts of confirmed patients.
Research into potential treatments is also progressing through the PARTNERS trial. This study is currently evaluating the effectiveness of monoclonal antibodies and antiviral medications to improve survival rates among those infected with the virus.
SOURCE: World Health Organization (WHO)
